keyword
https://read.qxmd.com/read/38484785/safety-and-efficacy-of-early-corticosteroid-withdrawal-in-liver-transplant-recipients-a-randomized-controlled-trial
#1
JOURNAL ARTICLE
Jongman Kim, Jae-Won Joh, Kwang-Woong Lee, Dong Lak Choi, Hee-Jung Wang
BACKGROUNDS/AIMS: Prolonged use of steroids after liver transplantation (LT) significantly increases the risk of diabetes or cardiovascular disease, which can adversely affect patient outcomes. Our study evaluated the effectiveness and safety of early steroid withdrawal within the first year following LT. METHODS: This study was conducted as an open-label, multicenter, randomized controlled trial. Liver transplant recipients were randomly assigned to one of the following two groups: Group 1, in which steroids were withdrawn two weeks posttransplantation, and Group 2, in which steroids were withdrawn three months posttransplantation...
March 15, 2024: Annals of Hepato-Biliary-Pancreatic Surgery
https://read.qxmd.com/read/38102386/factors-predicting-normalization-of-reproductive-hormones-after-cessation-of-anabolic-androgenic-steroids-in-men-a-single-center-retrospective-study
#2
JOURNAL ARTICLE
Bonnie Grant, John Campbell, Anjali Pradeep, Angela D Burns, Paul Bassett, Ali Abbara, Priyadarshi Saket, Sukhbinder Minhas, Waljit S Dhillo, James McVeigh, Shalender Bhasin, Channa N Jayasena
OBJECTIVE: Symptomatic hypogonadism discourages men from stopping anabolic-androgenic steroids (AAS). Some men illicitly take drugs temporarily stimulating endogenous testosterone following AAS cessation (post-cycle therapy; PCT) to lessen hypogonadal symptoms. We investigated whether prior PCT use was associated with the normalization of reproductive hormones following AAS cessation. METHODS: Retrospective analysis of 641 men attending a clinic between 2015-2022 for a single, nonfasting, random blood test <36 months following AAS cessation, with or without PCT...
December 6, 2023: European Journal of Endocrinology
https://read.qxmd.com/read/37942921/impact-of-baseline-corticosteroid-use-on-the-efficacy-and-safety-of-upadacitinib-in-patients-with-ulcerative-colitis-a-post-hoc-analysis-of-the-phase-3-clinical-trial-programme
#3
JOURNAL ARTICLE
Tim Raine, Yoh Ishiguro, David T Rubin, Tricia Finney-Hayward, Ramona Vladea, John Liu, Charles Phillips, Erica Cheng, Laura Targownik, Edward V Loftus
BACKGROUND AND AIMS: This post hoc analysis assessed the efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis stratified by corticosteroid use from the ulcerative colitis Phase 3 clinical trial programme. METHODS: Patients were randomised [1:2] to 8 weeks' placebo or upadacitinib 45 mg once daily [QD]; Week 8 responders were re-randomised [1:1:1] to 52 weeks' placebo, or upadacitinib 15 or 30 mg QD. Corticosteroid dose was kept stable during induction but tapered according to a protocol-defined schedule [or investigator discretion] during maintenance Weeks 0-8...
November 6, 2023: Journal of Crohn's & Colitis
https://read.qxmd.com/read/37819994/low-dose-tacrolimus-exposure-and-early-steroid-withdrawal-with-strict-body-weight-control-can-improve-post-kidney-transplant-glucose-tolerance-in-japanese-patients
#4
JOURNAL ARTICLE
Akihiko Mitsuke, Takahiko Ohbo, Junya Arima, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Hirofumi Yoshino, Shuichi Tatarano, Yasutoshi Yamada, Hajime Sasaki, Tatsu Tanabe, Nobuyuki Fukuzawa, Hiroshi Tanaka, Yoshihiko Nishio, Enokida Hideki, Hiroshi Harada
The development of diabetes mellitus (DM) after living donor kidney transplantation (KT) is a risk factor for worsening transplant kidney function, cardiac disease, and cerebrovascular disease, which may affect prognosis after KT. At our institution, all patients' glucose tolerance is evaluated perioperatively by oral glucose tolerance tests (OGTTs) at pre-KT, and 3, 6, and 12 month (mo.) after KT. We analyzed the insulinogenic index (ISI) and homeostasis model assessment beta cell (HOMA-β) based on the immunoreactive insulin (IRI) levels to determine how glucose tolerance changed after KT in 214 patients who had not been diagnosed with DM before KT...
2023: PloS One
https://read.qxmd.com/read/37392191/impact-of-early-corticosteroid-withdrawal-on-simultaneous-pancreas-kidney-transplant-long-term-outcomes-single-center-experience-and-comparison-to-the-international-pancreas-transplant-registry
#5
JOURNAL ARTICLE
Dana R Pierce, Angelika Gruessner, Maya Campara, Pierpaolo DiCocco, Mario Spaggiari, Ivo Tzvetanov, Ignatius Tang, Enrico Benedetti, Alicia B Lichvar
BACKGROUND: There remains a paucity of modern data comparing early steroid withdrawal (ESW) versus chronic corticosteroid (CCS) immunosuppression in simultaneous pancreas kidney (SPK) transplant recipients with long-term follow-up. Therefore, the purpose of this study is to assess the effectiveness and tolerability of ESW compared to CCS post-SPK. METHODS: This was a retrospective single-center matched comparison with the International Pancreas Transplant Registry (IPTR)...
July 1, 2023: Clinical Transplantation
https://read.qxmd.com/read/37018188/glucocorticoid-withdrawal-and-glucocorticoid-induced-adrenal-insufficiency-study-protocol-of-the-randomized-controlled-%C3%A2-toasst-taper-or-abrupt-steroid-stop-multicenter-trial
#6
JOURNAL ARTICLE
Mathis Komminoth, Marc Y Donath, Matthias Hepprich, Philipp Schuetz, Claudine A Blum, Beat Mueller, Jean-Luc Reny, Pauline Gosselin, Gautier Breville, Michael Brändle, Christoph Henzen, Jörg D Leuppi, Andreas D Kistler, Robert Thurnheer, Felix Beuschlein, Gottfried Rudofsky, Daniel Aeberli, Peter M Villiger, Stephan Böhm, Irina Chifu, Martin Fassnacht, Gesine Meyer, Jörg Bojunga, Marco Cattaneo, Constantin Sluka, Helga Schneider, Jonas Rutishauser
BACKGROUND: Despite the widespread use of glucocorticoids in inflammatory and autoimmune disorders, there is uncertainty about the safe cessation of long-term systemic treatment, as data from prospective trials are largely missing. Due to potential disease relapse or glucocorticoid-induced hypocortisolism, the drug is often tapered to sub-physiological doses rather than stopped when the underlying disease is clinically stable, increasing the cumulative drug exposure. Conversely, the duration of exposure to glucocorticoids should be minimized to lower the risk of side effects...
2023: PloS One
https://read.qxmd.com/read/36990111/efficacy-and-safety-of-mizoribine-in-comparison-with-cyclophosphamide-for-treatment-of-refractory-nephrotic-syndrome-protocol-for-a-multi-center-controlled-open-label-randomized-controlled-trial
#7
JOURNAL ARTICLE
Zheyi Dong, Jianhui Zhou, Zhonggao Xu, Zhaohui Ni, Yani He, Hongli Lin, Gengru Jiang, Xuefeng Sun, Li Zhang, Xiangmei Chen
BACKGROUND: Nephrotic syndrome that is resistant to steroidal therapy is termed refractory nephrotic syndrome (RNS), a condition that is associated with an increased risk of end-stage renal disease (ESRD). Immunosuppressants are utilized to treat RNS, however prolonged may lead to significant adverse effects. Mizoribine (MZR) is a novel agent used in long-term immunosuppressive therapy that has few adverse effects, but data on its long-term use in patients with RNS are unavailable. OBJECTIVE: We propose a trial to examine the efficacy and safety of MZR compared to cyclophosphamide (CYC) in Chinese adult patients with RNS...
March 28, 2023: JMIR Research Protocols
https://read.qxmd.com/read/36640794/withdrawal-of-infliximab-or-concomitant-immunosuppressant-therapy-in-patients-with-crohn-s-disease-on-combination-therapy-spare-a-multicentre-open-label-randomised-controlled-trial
#8
JOURNAL ARTICLE
Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig
BACKGROUND: The combination of infliximab and immunosuppressant therapy is a standard management strategy for patients with Crohn's disease. Concerns regarding the implications of long-term combination therapy provided the rationale for a formal clinical trial of treatment de-escalation. Our aim was to compare the relapse rate and the time spent in remission over 2 years between patients continuing combination therapy and those stopping infliximab or immunosuppressant therapy. METHODS: This multicentre, open-label, randomised controlled trial was performed in 64 hospitals in seven countries in Europe and Australia...
January 11, 2023: Lancet. Gastroenterology & Hepatology
https://read.qxmd.com/read/36570514/treatment-protocols-for-claw-horn-lesions-and-their-impact-on-lameness-recovery-pain-sensitivity-and-lesion-severity-in-moderately-lame-primiparous-dairy-cows
#9
JOURNAL ARTICLE
Mohammed Babatunde Sadiq, Siti Zubaidah Ramanoon, Wan Mastura Shaik Mossadeq, Rozaihan Mansor, Sharifah Salmah Syed-Hussain
This study aims to investigate the effects of routine treatment protocols for claw horn disruptive lesions (CHDL) on lameness recovery rates, pain sensitivity, and lesion severity in moderately lame primiparous cows. A cohort of first parity cows was recruited from a single commercial dairy herd and randomly allocated to five treatments, comprising four lame groups (LTNB, LTN, LTB, and LT) and a single group non-lame group. Eligibility criteria for the lame cows included a first lameness score (score 3/5), presence of CHDL on a single foot, good body condition score of 3...
2022: Frontiers in Veterinary Science
https://read.qxmd.com/read/36081515/immune-tolerance-induced-by-hematopoietic-stem-cell-infusion-after-hla-identical-sibling-kidney-transplantation
#10
JOURNAL ARTICLE
Hongfeng Huang, Qixia Shen, Jingyi Zhou, Xiuyan Yang, Qiuqin Cai, Jia Shen, Shi Feng, Wenqing Xie, Hong Jiang, Jianghua Chen
After the first attempt to induce operational tolerance, it has taken decades to implement it in clinical practice. Recipients with Human leukocyte antigen (HLA) identical sibling donors were enrolled. Hematopoietic stem cells (HSCs) infusion was done after HLA identical sibling kidney transplantation (KTx). Three cases included were followed up for over 8 years. The perioperative conditioning protocol included anti-CD20, rabbit anti-thymocyte globulin (ATG), total lymphoid irradiation (TLI), and cyclophosphamide...
2022: Frontiers in Immunology
https://read.qxmd.com/read/35980172/surgery-and-perioperative-management-of-patients-with-cushing-s-disease
#11
REVIEW
Juergen Honegger, Isabella Nasi-Kordhishti
Transsphenoidal surgery (TSS) is the initial treatment modality of first choice in Cushing's disease (CD). With microscopic TSS and endoscopic TSS, two operative techniques with equally favourable remission rates and operative morbidity are available. On average, remission is achieved with primary TSS in 80% of patients with microadenomas and 60% of patients with macroadenomas. The current literature indicates that remission rates in repeat TSS for microadenomas can also exceed 70%. Experience with TSS in CD plays an important role in the success rate and centralization in Pituitary Centres of Excellence has been proposed...
August 2022: Journal of Neuroendocrinology
https://read.qxmd.com/read/35945790/bipolar-type-i-diagnosis-after-a-manic-episode-secondary-to-sars-cov-2-infection-a-case-report
#12
JOURNAL ARTICLE
Ambra D'Imperio, Jonathan Lo, Luca Bettini, Paco Prada, Guido Bondolfi
RATIONALE: Our objective is to provide awareness about psychotic vulnerability in patients infected with SARS-CoV-2 and to better understand the role of steroid withdrawal in manic episodes, especially with its common usage in respiratory disease caused by SARS-CoV-2. PATIENT CONCERNS: We present the case of a patient who was hospitalized twice after discontinuing steroid therapy for SARS-CoV-2 infection and presented with a manic episode despite not having a psychiatric history...
August 5, 2022: Medicine (Baltimore)
https://read.qxmd.com/read/35384800/immunosuppression-compliance-and-tolerance-after-orthotopic-liver-transplantation-state-of-the-art
#13
JOURNAL ARTICLE
Noemi Zorzetti, Augusto Lauro, Simone Khouzam, Ignazio Roberto Marino
Orthotopic liver transplantation is the treatment of choice for several otherwise irreversible forms of acute and chronic liver diseases. Early implemented immunosuppressant regimens have had disappointing results with high rejection rates. However, new drugs have reduced the daily immunosuppression requirements, thereby improving graft and patient survival as well as kidney function. Liver rejection is a T-cell-driven immune response and is the active target of immunosuppressive agents. Immunosuppressants can be divided into pharmacological or biological drugs: the gold standard is the calcineurin inhibitors, steroids, mycophenolate mofetil, and mechanistic target of rapamycin inhibitors...
March 2022: Experimental and Clinical Transplantation
https://read.qxmd.com/read/34845071/randomised-controlled-trial-comparing-rituximab-to-mycophenolate-mofetil-in-children-and-young-adults-with-steroid-dependent-idiopathic-nephrotic-syndrome-study-protocol
#14
JOURNAL ARTICLE
Francesca Lugani, Andrea Angeletti, Pietro Ravani, Marina Vivarelli, Manuela Colucci, Gianluca Caridi, Enrico Verrina, Francesco Emma, Gian Marco Ghiggeri
INTRODUCTION: Glucocorticoids induce remission in 90% of children with idiopathic nephrotic syndrome (INS). Some become steroid-dependent (SD) and require the addition of steroid sparing drugs such as calcineurin-inhibitors (CNI) or cyclophosphamide, to maintain remission. Considering the toxicity of these drugs, alternative interventions are needed for long-term treatment. The anti-CD20 antibody rituximab has shown promising steroid-sparing properties, with conflicting results in complicated forms of SD-INS...
November 29, 2021: BMJ Open
https://read.qxmd.com/read/34807989/macrolides-versus-placebo-for-chronic-asthma
#15
REVIEW
Krishna Undela, Lucy Goldsmith, Kayleigh M Kew, Giovanni Ferrara
BACKGROUND: Asthma is a chronic disease in which inflammation of the airways causes symptomatic wheezing, coughing and difficult breathing. Macrolides are antibiotics with antimicrobial and anti-inflammatory activities that have been explored for the long-term control of asthma symptoms. OBJECTIVES: To assess the effects of macrolides compared with placebo for managing chronic asthma. SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register up to March 2021...
November 22, 2021: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/34774307/patient-and-graft-survival-outcomes-during-2-eras-of-immunosuppression-protocols-in-kidney-transplantation-indiana-university-retrospective-cohort-experience
#16
JOURNAL ARTICLE
Oluwafisayo Adebiyi, Peter Umukoro, Asif Sharfuddin, Tim Taber, Jeanne Chen, Kathleen A Lane, Xiaochun Li, Williams Goggins, Muhammad S Yaqub
BACKGROUND: Since 1964 when Indiana University performed its first kidney transplant, immunosuppression protocol was steroid-based until 2004 when steroid-free immunosuppression protocol was adopted. We describe clinical outcomes on our patients administered early steroid withdrawal (ESW) protocol (5 days) compared with our historical cohort (HC), who were on chronic steroid-based immunosuppression. METHODS: We performed a retrospective study evaluating kidney transplant recipients between 1993 and 2003 (HC, n = 1689) and between 2005 and 2016 (ESW cohort, n = 2097) at the Indiana University program, with a median follow-up of 10...
November 10, 2021: Transplantation Proceedings
https://read.qxmd.com/read/34761712/the-role-of-systemic-corticosteroids-in-severe-asthma-and-new-evidence-in-their-management-and-tapering
#17
JOURNAL ARTICLE
Francesco Menzella, Giulia Ghidoni, Matteo Fontana, Silvia Capobelli, Francesco Livrieri, Claudia Castagnetti, Nicola Facciolongo
INTRODUCTION: Based on the latest literature evidence, between 30% and 60% of adults with severe refractory asthma (SRA) are systemic corticosteroid (SCS) dependent. There are numerous therapeutic options in asthma, which are often not effective in severe forms. In these cases, SCS should be considered, but it is increasingly recognized that their regular use is often associated with significant and potentially serious adverse events. AREAS COVERED: The aim of this article is to provide an update about the recent and significant literature on SCS and to establish their role in the management of SRA...
December 2021: Expert Review of Clinical Immunology
https://read.qxmd.com/read/34669312/-steroidi-tra-necessit%C3%A3-e-tossicit%C3%A3
#18
JOURNAL ARTICLE
Silvio Sandrini, Stefania Affatato, Bernardo Lucca
Steroid minimization has always been one of the most desired goals regarding immunosuppressive therapy after renal transplantation. Following the introduction of cyclosporine different steroid-free protocols became available, but their implementation was limited due to the high risk of acute rejection. In the last few years, the use of a very low dose of prednisone (5 mg/day) has been deemed to guarantee a good balance between steroid toxicity and efficacy. However, high interpatient variability in prednisolone exposure prevented the standard low dose to be as safe as expected in all patients...
September 7, 2021: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://read.qxmd.com/read/34668614/steroid-withdrawal-after-heart-transplantation-in-adults
#19
REVIEW
Benedicte Heegaard, Laerke Marie Nelson, Finn Gustafsson
Corticosteroids (CSs) are a key component of immunosuppressive treatment after heart transplantation (HTx). While effectively preventing acute rejection, several adverse effects including diabetes, hypertension, osteoporosis, and hyperlipidemia are associated with long-term use. As these complications may impair long-term outcome in HTx recipients, withdrawal of CSs is highly desirable, however, no uniform approach exists. Previous experience suggests that CS withdrawal can be accomplished without an increase in the incidence of acute rejection and even carrying a survival benefit...
December 2021: Transplant International
https://read.qxmd.com/read/34503460/study-protocol-for-optimalttf-2-enhancing-tumor-treating-fields-with-skull-remodeling-surgery-for-first-recurrence-glioblastoma-a-phase-2-multi-center-randomized-prospective-interventional-trial
#20
RANDOMIZED CONTROLLED TRIAL
N Mikic, F R Poulsen, K B Kristoffersen, R J Laursen, T L Guldberg, J Skjøth-Rasmussen, E T Wong, S Møller, R H Dahlrot, J C H Sørensen, A R Korshøj
BACKGROUND: OptimalTTF-2 is a randomized, comparative, multi-center, investigator-initiated, interventional study aiming to test skull remodeling surgery in combination with Tumor Treating Fields therapy (TTFields) and best physicians choice medical oncological therapy for first recurrence in glioblastoma patients. OptimalTTF-2 is a phase 2 trial initiated in November 2020. Skull remodeling surgery consists of five burrholes, each 15 mm in diameter, directly over the tumor resection cavity...
September 9, 2021: BMC Cancer
keyword
keyword
161557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.